Millions more people with overweight could benefit from GLP-1 drugs to protect heart health, study suggests

New probe being presented astatine the yearly gathering of the European Association for the Study of Diabetes (EASD) successful Milan, Italy, Sept. 28–Oct. 2, makes a lawsuit for extending the denotation for GLP-1 receptor agonists (GLP1-RAs) to millions much radical to support their bosom health.